Universal pharmacare benefits business and working families
By Anita Huberman & Hassan YussuffFeb. 25, 2019
The federal government can be on the right side of history as the upcoming election looms. Or, it can offer costly half measures that mostly benefit big pharma and the insurance industries and leave the rest of us out in the cold. The choice is clear.
This is the unfinished business of medicare, as contemplated by Tommy Douglas, right, pictured with Thérèse Casgrain in 1995, the visionary of our cherished health-care system, write Anita Huberman and Hassan Yussuff. Photograph courtesy of Wikimedia Commons
Every government struggles with how best to support the people it serves. One hopes and assumes that decisions are based on thorough research, meaningful consultations, and with the guidance of experts in the field.
People. Policy. Politics. This is an exclusive subscriber-only story.
Going Green Key players, committee meetings, debates, highlights from Question Period, press releases on Bill C-45, The Cannabis Act, as well as stories on the topic. Get the book
The federal response to the opioid crisis Summarizes the work on the opioid crisis that is going on at the federal level: what the House of Commons and the Senate have been listening to and acting on to help stop and mitigate this tragedy. Get the book
Hill Times Research The daily tracking service for Health Industry Professionals. Curated health news and analysis. Get the research
Politics This Morning
Your email has been added. An email has been sent to your address, please click the link inside of it to confirm your subscription.